Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics is offering 20,000,000 shares of its common stock at a public offering price of $5.00 per share. The offering includes an underwriter option to purchase up to an additional 3,000,000 shares. Delivery of the shares is expected on or about February 27, 2026.
The cover page shows underwriting discounts of $0.30 per share and proceeds to the company before expenses of $94,000,000. The offering is being made from a shelf registration on Form S-3 and assumes no exercise of outstanding options; management retains broad discretion over use of proceeds.
Larimar Therapeutics is offering $75.0 million of common stock and associated pre‑funded warrants. The prospectus supplement outlines an at‑the‑market shelf background and an underwritten offering that includes a 30‑day option for up to an additional $11.25 million of common stock.
The company reports unaudited preliminary cash, cash equivalents and marketable securities of $136.9 million as of December 31, 2025. The filing notes FDA Breakthrough Therapy Designation for nomlabofusp and a planned BLA submission targeted for June 2026. The prospectus discloses 80,590,392 shares outstanding as the base for post‑offering calculations and describes usual issuance, dilution, lock‑up and underwriting terms.
Larimar Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, recognizing preliminary data that suggest substantial improvement over existing therapy. Following a START pilot program meeting, the FDA signaled continued alignment on using skin frataxin (FXN) as a novel surrogate endpoint to support a Biologics License Application seeking accelerated approval.
The company expects topline data from its ongoing open-label study in Q2 2026, plans to submit the BLA in June 2026, and is targeting a potential U.S. launch in the first half of 2027, if approved. A global confirmatory Phase 3 study is planned to start screening in Q2 2026, with Upright Stability Score as the primary endpoint. Larimar estimates it had $136.9 million in cash and investments as of December 31, 2025, with a projected runway into Q4 2026.
Larimar Therapeutics, Inc. received an amended ownership report showing that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah now report beneficial ownership of 0 shares of Larimar common stock as of December 31, 2025.
Each reporting person lists 0.0% of the common stock class, with no sole or shared voting or dispositive power. They also state that any securities referenced were not acquired or held for the purpose of changing or influencing control of Larimar Therapeutics.
Blue Owl Capital Holdings LP filed an amended Schedule 13G reporting beneficial ownership of 8,464,663 Larimar Therapeutics common shares, representing 9.99 % of the class. This total includes 6,823,690 common shares and 1,640,973 shares issuable upon conversion of 250,000 Series A convertible preferred shares, which are subject to a 9.9% conversion blocker.
Blue Owl reports sole voting and dispositive power over all of these securities and states they were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Larimar Therapeutics.
Larimar Therapeutics reported an insider equity award for Chief Development Officer Shankar Gopi. On January 26, 2026, he received 153,822 stock options with a $3.60 exercise price and vesting over four years, starting 25% on January 26, 2027, then monthly thereafter.
He also acquired 25,637 shares of common stock for $0.00 per share, represented by restricted stock units, bringing his directly held common stock to 76,443 shares. All transactions were classified as awards and reported as directly owned.
Larimar Therapeutics Chief Medical Officer Clayton Russell received new equity awards. On January 26, 2026, he was granted 25,637 restricted stock units, representing the right to receive an equal number of Larimar common shares at settlement, bringing his directly held common stock to 71,443 shares.
He was also granted stock options for 153,822 shares at an exercise price of $3.60. These options vest 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.
Larimar Therapeutics President and CEO Carole Ben-Maimon reported equity awards dated January 26, 2026. She received 100,100 shares of Common Stock for no cash cost, structured as restricted stock units that each convert into one share upon settlement.
She was also granted a stock option for 600,600 shares of Common Stock at an exercise price of $3.60 per share. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to her continued service. After these grants, she directly holds 368,276 shares of Common Stock and 600,600 stock options, while several irrevocable family trusts for which she serves as trustee each hold 31,155 or 31,156 shares; she disclaims beneficial ownership of those trust shares except to any pecuniary interest.
Larimar Therapeutics reported an equity compensation grant to its Chief Financial Officer, Michael Celano. On January 26, 2026, he received 37,604 shares of Common Stock at a price of $0.00 per share, represented by restricted stock units that each convert into one share upon settlement. Following this award, he beneficially owned 215,785 shares of Common Stock directly. The same day, he was also granted a stock option covering 225,622 shares of Common Stock with a $3.6 exercise price per share. This option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, contingent on his continued service, and expires on January 26, 2036.
Larimar Therapeutics, Inc. entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, where the investor will exchange 2,500,000 shares of Larimar common stock for 250,000 shares of Series A convertible preferred stock. Each preferred share is convertible into 10 common shares, but the preferred stock generally carries no voting rights and shares in liquidation proceeds on the same basis as common stock, subject to its ranking terms. In connection with this exchange, Larimar amended the existing designation to increase authorized Series A preferred shares from 250,000 to 500,000. The exchange is expected to close on January 23, 2026, and the preferred shares will be issued without registration under the Securities Act in reliance on Section 3(a)(9).